Do R&D Spending And Approvals Really Measure Innovation?
CBO Report Suggests There’s A Bigger Story Than Numbers Tell
A lot of new drugs aren’t really all that innovative, which complicates the view that lower profitability will mean less biopharma innovation.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.
Pharma’s Upcoming Messaging Battles In US Pricing Debate Foreshadowed In CBO Report
Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.
COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.